DexCom, Inc. $DXCM Shares Sold by American Century Companies Inc.

American Century Companies Inc. cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 47.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,492,647 shares of the medical device company’s stock after selling 2,235,590 shares during the period. American Century Companies Inc. owned approximately 0.64% of DexCom worth $167,730,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Andra AP fonden acquired a new stake in DexCom during the 2nd quarter worth about $26,000. Twin Peaks Wealth Advisors LLC acquired a new position in DexCom during the second quarter valued at $26,000. SJS Investment Consulting Inc. lifted its stake in DexCom by 4,800.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after acquiring an additional 384 shares in the last quarter. Financial Consulate Inc. acquired a new position in shares of DexCom in the 3rd quarter valued at about $29,000. Finally, Sound Income Strategies LLC boosted its holdings in shares of DexCom by 83.8% during the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. UBS Group lowered their price target on shares of DexCom from $106.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, November 3rd. Evercore started coverage on shares of DexCom in a research report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target on the stock. Citigroup reaffirmed a “buy” rating and set a $77.00 price objective (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Finally, Canaccord Genuity Group set a $95.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $85.18.

DexCom Stock Down 1.3%

Shares of DXCM opened at $73.43 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59. The company has a market cap of $28.26 billion, a P/E ratio of 34.97, a P/E/G ratio of 1.43 and a beta of 1.48. DexCom, Inc. has a one year low of $54.11 and a one year high of $89.98. The firm has a 50 day simple moving average of $70.24 and a two-hundred day simple moving average of $69.08.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.45 earnings per share. Research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.